|
|
|
|
 |
|||
|
|||
ARTICLE |
Splicing Mutations in TP53 in Human Squamous Cell Carcinoma Lines Influence Immunohistochemical Detection
Wolfgang Eichelera, Daniel Zipsa, Annegret Dörflera, Reidar Grénmanc, and Michael Baumanna,ba Department of Radiotherapy and Radiation Oncology, Turku University, Turku, Finland
b Experimental Center, Turku University, Turku, Finland
c Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany, and Department of Otorhinolaryngology–Head and Neck Surgery and Department of Medical Biochemistry, Turku University, Turku, Finland
Correspondence to: Wolfgang Eicheler, Uniklinikum, Klinik für Strahlentherapie und Radioonkologie, Fetscherstr. 74, 01307 Dresden, Germany. E-mail: wolfgang.eicheler@mailbox.tu-dresden.de
The mutational status of the tumor suppressor gene TP53 is often examined by immunohistochemistry. We compared the incidence of TP53 mutations in 12 permanent squamous cell carcinoma lines of the head and neck with the immunohistochemical staining obtained with two different antibodies. The mutational status of the TP53 gene was assessed by sequencing the complete coding frame of the TP53 mRNA. All 12 tumor cell lines had TP53 mutations. Six of them showed missense mutations and five had premature stop codons caused either by splicing mutations or nonsense mutations or by exon skipping. One tumor cell line was heterozygous, with a truncating splicing mutation and an additional missense mutation located on different alleles. In one case, an in-frame insertion of 23 extra codons was found. All missense mutations were positive in immunhistochemistry and Western blotting. The truncated p53 was not immunohistochemically detected in three cases with the DO-7 antibody and in five cases with the G59-12 antibody, giving false-negative results in 25% or 40%, respectively, of all tumor cell lines examined. We conclude that splicing mutations are common in squamous cell carcinoma lines and that the incidence of p53 inactiviation by erroneous splicing is higher than yet reported. Sequencing of only the exons of TP53 may miss intronic mutations leading to missplicing and may therefore systematically underestimate the TP53 mutation frequency.
(J Histochem Cytochem 50:197–204, 2002)
Key Words: p53, squamous cell carcinoma, mutation, immunohistochemistry, splicing, exon skipping
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. V. Lund, M. Popkov, L. Magnenat, and C. F. Barbas III Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErbB2 and ErbB3 Receptors: Insights into ErbB Receptor Biology Mol. Cell. Biol., October 15, 2005; 25(20): 9082 - 9091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Balz, K. Scheckenbach, K. Gotte, U. Bockmuhl, I. Petersen, and H. Bier Is the p53 Inactivation Frequency in Squamous Cell Carcinomas of the Head and Neck Underestimated? Analysis of p53 Exons 2-11 and Human Papillomavirus 16/18 E6 Transcripts in 123 Unselected Tumor Specimens Cancer Res., March 15, 2003; 63(6): 1188 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anelli, R. R. Brentani, A. P. Gadelha, A. Amorim de Albuquerque, and F. Soares Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer Ann. Onc., March 1, 2003; 14(3): 428 - 432. [Abstract] [Full Text] [PDF]
|
|
| Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact |